News

Company to host conference call tomorrow, Tuesday, August 15, 2023, at 8:30 AM EDT. SEATTLE, Wash and VANCOUVER, British Columbia, August 14, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced second quarter…

SEATTLE, WA and VANCOUVER, British Columbia, August 1, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its second quarter 2023 financial results on Monday, August 14, 2023, and…

SEATTLE, Wash and VANCOUVER, British Columbia, July 18, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced participation on a panel during the 2023 American Society of Pharmacognosy (ASP) Annual Meeting, being held…

Cytisinicline 6- and 12-week dosing schedules, with behavioral support, demonstrated “smoking cessation efficacy and excellent tolerability”  Supports potential for cytisinicline to be the first pharmacotherapy approved for smoking cessation in nearly two decades.  SEATTLE, Wash and VANCOUVER, British Columbia, July 11, 2023 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), today announced the publication in JAMA…

SEATTLE and VANCOUVER, British Columbia, June 6, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that John Bencich, CEO of Achieve, will be presenting at the LD Micro Invitational XIII in Los…